TCON News and Press, TRACON Pharmaceuticals Inc. From 11/29/21

TRACON Pharmaceuticals (NASDAQ:TCON) reports that its partners Alphamab Oncology and 3D Medicines (Beijing) Co., Ltd. have announced that envafolimab (KN035), the world's first single-domain PD-L1 antibody formulated for subcutaneous injection received marketing authorization from the Chinese...

First Approval of a Subcutaneously Administered Checkpoint Inhibitor TRACON’s Pivotal U.S. Trial for Envafolimab in Undifferentiated Pleomorphic Sarcoma and Myxofibrosarcoma Continues to Advance as Planned SAN DIEGO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmace...

In a $480 million deal, Zenas, a Shanghai-Boston biopharma, acquired global rights to a bifunctional antibody from Xencor that targets CD19. Beijing's BeiGene closed on a 42-acre US site in the Princeton, NJ area where it will build a manufacturing center and house clinical R&D op...

SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform ...

TRACON Pharmaceuticals, Inc. (TCON) Q3 2021 Earnings Conference Call November 03, 2021 4:30 PM ET Company Participants Charles Theuer - President and Chief Executive Officer Scott Brown - Chief Financial Officer Conference Call Participants Nicholas Abbott - Wells Fargo Maurice Raycroft - Jef...

Tracon (NASDAQ:TCON): Q3 GAAP EPS of -$0.38 misses by $0.05. Cash, cash equivalents and short-term investments were $29.9 million at September 30, 2021, compared to $36.1 million at December 31, 2020. Press release. For further details see: Tracon EPS misse...

SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform t...

SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform t...

Hansoh Pharma of Shanghai announced a $456 million agreement to develop siRNA products in Greater China from South Korea's OliX Pharma. The $1.4 billion landmark deal between Beijing's BeiGene and Celgene (now Bristol-Myers) is falling apart. The companies are arguing over BeiGene's C...

SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing a product development platform to partner with ex-U.S. compa...